Open

Full sponsor guidelines are linked here. 
 

Request Ticket // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution (normally identified by having a unique UEI or NIH IPF number) is allowed.

Purpose
This Notice of Funding Opportunity (NOFO) invites applications from clinical centers to participate in a consortium to test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs.  Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscripts. 

Full sponsor guidelines are linked here. 

Request Ticket // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution (normally identified by having a unique entity identifier (UEI) number or NIH IPF number) is allowed.

Purpose
The purpose of this notice of funding opportunity (NOFO) is to solicit applications for the Atopic Dermatitis Research Network (ADRN) program. The ADRN program will support Centers that integrate clinical and translational research to improve our understanding and management of atopic dermatitis with emphasis on chronic skin inflammation and the defense mechanisms of the skin.

Full sponsor guidelines are linked here. 

Request Ticket // Limit: 2 // Tickets Available: 2

Limiting Language 
Only two applications per institution (identified by Unique Entity Identifier (UEI) number or NIH IPF number) are allowed.

Program Description
Full sponsor guidelines are linked here.

The NIH Director's Early Independence Award helps talented new researchers begin their own independent research program soon after finishing their doctoral degree or clinical training, without first doing postdoctoral training.The award accepts applications on any topic fitting the NIH mission. It is part of the NIH Common Fund's High-Risk, High-Reward Research program.

Eligible Individuals (Program Director/Principal Investigator)
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. 

Requirements

• One PD/PI only: Applications can have only one PD/PI. Multiple PD/PIs are not allowed. Only the PD/PI may be listed as Senior/Key Personnel and submit a biosketch.
• Citizenship: U.S. citizenship is not required. If the PD/PI is not a U.S. citizen, the institution must ensure the visa permit allows them to do the proposed research in the U.S. for the full project period.
• Degree or clinical training dates: The PD/PI must complete their terminal doctoral degree or post-graduate clinical training between May 1, 2025, and September 30, 2027.
  • The date shown on the official transcript is considered the date the degree was completed.
  • Clinical training includes residency and fellowship.
  • At the time of award, either:
    • The PD/PI must have an eligible doctoral degree from an accredited U.S. or foreign institution, oR
    • An authorized official must confirm all degree requirements are complete and the degree will be awarded before September 30, 2027.
• Post-doctoral experience: The PD/PI must not have more than 12 months of postdoctoral training after an earlier, non-terminal doctoral degree. This applies only to individuals with multiple doctoral degrees.
• Effort required:
  • Years 1-2: At least 9.6 person-months per year (80% effort) on the award project
  • Years 3-5:  At least 9.6 person-months per year (80% effort) on independent research overall, including the award project and any other independent research led by the PD/PI.
• Non-independence required: At the time of application, the PD/PI must still be non-independent. All the following must apply:
  • Research direction requires mentor approval
  • Research is mainly supported through another investigator's funding (mentored fellowships, such as an NIH F31/F32 or NSF Graduate Research Fellowship, do not make an applicant ineligible)
  • No institutionally assigned research space
  • Cannot apply for an NIH R01 without a special institutional waiver or exception

The PD/PI may become independent before the award starts and still remain eligible.

• Independent position required: The PD/PI must have a guaranteed, pending independent research position and be able to begin independent research by the project start date.
  • The position does not have to be permanent or tenure-track.
  • The position may depend on receiving this award.
  • The institution must provide substantial support, as described in the application.
  • Moving to a new institution may be advantageous but is not required.
• Career awards: ThePD/PI may apply for both a K award and DP5 simultaneously, but the projects must not overlap scientifically. A PD/PI cannot hold both simultaneously; if awarded the DP5, the K award must be relinquished.
• Site visit: NIH will conduct a site visit near the end of the first year to assess progress and confirm institutional support and independence. If support is insufficient, NIH may take corrective action, including reducing or terminating funding.